Liraglutide

Results: 53



#Item
41SAXAGLIPTIN ADVISORY COMMITTEE MEETING

SAXAGLIPTIN ADVISORY COMMITTEE MEETING

Add to Reading List

Source URL: www.fda.gov

Language: English
4224 July 2014 EMA/CHMP[removed]Committee for Medicinal Products for Human Use (CHMP) Summary of opinion 1 (initial authorisation)

24 July 2014 EMA/CHMP[removed]Committee for Medicinal Products for Human Use (CHMP) Summary of opinion 1 (initial authorisation)

Add to Reading List

Source URL: www.ema.europa.eu

Language: English - Date: 2014-07-25 07:07:29
43HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Victoza safely and effectively. See full prescribing information for Victoza. ···················

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Victoza safely and effectively. See full prescribing information for Victoza. ···················

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2012-12-18 15:58:18
44HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Victoza safely and effectively. See full prescribing information for Victoza. ···················

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Victoza safely and effectively. See full prescribing information for Victoza. ···················

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2013-04-17 15:29:04
45HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Victoza safely and effectively. See full prescribing information for Victoza. ···················

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Victoza safely and effectively. See full prescribing information for Victoza. ···················

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2012-04-09 17:09:18
46Department of Vermont Health Access Pharmacy Benefit Management Program DUR Board Meeting Minutes: [removed]Board Members: Present: Joseph Lasek, MD, Chair

Department of Vermont Health Access Pharmacy Benefit Management Program DUR Board Meeting Minutes: [removed]Board Members: Present: Joseph Lasek, MD, Chair

Add to Reading List

Source URL: dvha.vermont.gov

Language: English - Date: 2012-11-06 14:16:29
47Canadian Adverse Reaction Newsletter Volume 23 • Issue 2 • April 2013 www.health.gc.ca/carn In this issue Intraocular lenses and the

Canadian Adverse Reaction Newsletter Volume 23 • Issue 2 • April 2013 www.health.gc.ca/carn In this issue Intraocular lenses and the

Add to Reading List

Source URL: www.hc-sc.gc.ca

Language: English - Date: 2013-06-24 11:45:03
48APPENDIX A: REMS 	 Initial REMS approval: [removed]Most recent modification: [removed]NDA[removed]VICTOZA® (liraglutide [rDNA origin] injection) Novo Nordisk Inc.

APPENDIX A: REMS Initial REMS approval: [removed]Most recent modification: [removed]NDA[removed]VICTOZA® (liraglutide [rDNA origin] injection) Novo Nordisk Inc.

Add to Reading List

Source URL: www.fda.gov

Language: English
49Liraglutide Suppresses Obesity and Hyperglycemia Associated with Increases in Hepatic Fibroblast Growth Factor 21 Production in KKAy Mice

Liraglutide Suppresses Obesity and Hyperglycemia Associated with Increases in Hepatic Fibroblast Growth Factor 21 Production in KKAy Mice

Add to Reading List

Source URL: www.ncbi.nlm.nih.gov

Language: English
50ISSN[removed] © Am J Case Rep, 2014; 15: [removed]DOI: [removed]AJCR[removed]

ISSN[removed] © Am J Case Rep, 2014; 15: [removed]DOI: [removed]AJCR[removed]

Add to Reading List

Source URL: www.ncbi.nlm.nih.gov

Language: English